Mwanzo0460 • HKG
add
Sihuan Pharmaceutical Holdings Group Ltd
Bei iliyotangulia
$ 0.59
Bei za siku
$ 0.57 - $ 0.59
Bei za mwaka
$ 0.49 - $ 1.02
Thamani ya kampuni katika soko
5.40B HKD
Wastani wa hisa zilizouzwa
12.69M
Uwiano wa bei na mapato
-
Mgao wa faida
3.62%
Ubadilishanaji wa msingi
HKG
Habari za soko
The Straits Times
siku 1 iliyopita
Nasdaq closes lower, S&P 500 up slightly as US yields stay elevated
0.11%
0.092%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CNY) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 474.85M | -10.04% |
Matumizi ya uendeshaji wa biashara | 301.93M | -12.13% |
Mapato halisi | -16.71M | 32.67% |
Kiwango cha faida halisi | -3.52 | 25.11% |
Mapato kwa kila hisa | — | — |
EBITDA | 56.91M | -32.62% |
Asilimia ya kodi ya mapato | -253.73% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CNY) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 4.86B | 7.86% |
Jumla ya mali | 11.53B | -2.11% |
Jumla ya dhima | 6.44B | -1.32% |
Jumla ya hisa | 5.09B | — |
hisa zilizosalia | 9.32B | — |
Uwiano wa bei na thamani | 1.26 | — |
Faida inayotokana na mali | 0.05% | — |
Faida inayotokana mtaji | 0.09% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CNY) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -16.71M | 32.67% |
Pesa kutokana na shughuli | 18.23M | 28.75% |
Pesa kutokana na uwekezaji | 126.63M | 152.35% |
Pesa kutokana na ufadhili | -29.16M | 73.91% |
Mabadiliko halisi ya pesa taslimu | 115.70M | 344.01% |
Mtiririko huru wa pesa | -12.85M | -53.24% |
Kuhusu
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province. The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.
Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease. The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2001
Tovuti
Wafanyakazi
2,648
